{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T23:00:01Z","timestamp":1778799601195,"version":"3.51.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1SH6A24N"],"award-info":[{"award-number":["1SH6A24N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s15010-025-02663-0","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T07:32:11Z","timestamp":1760427131000},"page":"299-313","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A fluconazole population pharmacokinetics study to improve target attainment in critically ill patients"],"prefix":"10.1007","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9203-6745","authenticated-orcid":false,"given":"My-Luong","family":"Vuong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5708-9497","authenticated-orcid":false,"given":"Omar","family":"Elkayal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8353-2103","authenticated-orcid":false,"given":"Ruth","family":"Van Daele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6703-0288","authenticated-orcid":false,"given":"Jan-Willem C.","family":"Alffenaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2114-587X","authenticated-orcid":false,"given":"Sophie L.","family":"Stocker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6218-435X","authenticated-orcid":false,"given":"Jason A.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1784-8297","authenticated-orcid":false,"given":"Yves","family":"Debaveye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5983-3897","authenticated-orcid":false,"given":"Joost","family":"Wauters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1501-3045","authenticated-orcid":false,"given":"Beatrijs","family":"Mertens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5957-7244","authenticated-orcid":false,"given":"Jasper M.","family":"Boonstra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9457-8262","authenticated-orcid":false,"given":"Indy","family":"Sandaradura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah J. E.","family":"Marriott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7618-725X","authenticated-orcid":false,"given":"Roger J.","family":"Br\u00fcggemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9118-4420","authenticated-orcid":false,"given":"Jeroen A.","family":"Schouten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7965-1273","authenticated-orcid":false,"given":"Raoul","family":"Bergner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Buijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6342-0676","authenticated-orcid":false,"given":"Isabel","family":"Spriet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0785-2930","authenticated-orcid":false,"given":"Erwin","family":"Dreesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"issue":"Suppl 7","key":"2663_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/1469-0691.12039","volume":"18","author":"OA Cornely","year":"2012","unstructured":"Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012;18(Suppl 7):19\u201337. https:\/\/doi.org\/10.1111\/1469-0691.12039","journal-title":"Clin Microbiol Infect"},{"key":"2663_CR2","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13613-020-00755-8","volume":"10","author":"M Schroeder","year":"2020","unstructured":"Schroeder M, Weber T, Denker T, Winterland S, Wichmann D, Rohde H, et al. Epidemiology, clinical characteristics, and outcome of candidemia in critically ill patients in germany: a single-center retrospective 10-year analysis. Ann Intensiv Care. 2020;10:142. https:\/\/doi.org\/10.1186\/s13613-020-00755-8","journal-title":"Ann Intensiv Care"},{"key":"2663_CR3","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s13054-019-2497-3","volume":"23","author":"M Bassetti","year":"2019","unstructured":"Bassetti M, Giacobbe DR, Vena A, Trucchi C, Ansaldi F, Antonelli M, et al. Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in europe: results of the EUCANDICU project. Crit Care. 2019;23:219. https:\/\/doi.org\/10.1186\/s13054-019-2497-3","journal-title":"Crit Care"},{"key":"2663_CR4","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s11739-017-1783-9","volume":"13","author":"F Sbrana","year":"2018","unstructured":"Sbrana F, Sozio E, Bassetti M, Ripoli A, Pieralli F, Azzini AM, et al. Independent risk factors for mortality in critically ill patients with candidemia on Italian internal medicine wards. Intern Emerg Med. 2018;13:199\u2013204. https:\/\/doi.org\/10.1007\/s11739-017-1783-9","journal-title":"Intern Emerg Med"},{"key":"2663_CR5","unstructured":"Pfizer. Summary of Product Characteristics (SmPC) Diflucan. Summary of Product Characteristics (SmPC) Diflucan. 2012."},{"key":"2663_CR6","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/civ933","volume":"62","author":"PG Pappas","year":"2016","unstructured":"Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;62:e1\u201350. https:\/\/doi.org\/10.1093\/cid\/civ933","journal-title":"Clin Infect Dis"},{"key":"2663_CR7","doi-asserted-by":"publisher","first-page":"527","DOI":"10.2147\/ceor.S91587","volume":"7","author":"S Grau","year":"2015","unstructured":"Grau S, Pozo JC, Rom\u00e1 E, Salavert M, Barrueta JA, Peral C, et al. Cost-effectiveness of three echinocandins and fluconazole in the treatment of candidemia and\/or invasive candidiasis in nonneutropenic adult patients. Clinicoecon Outcomes Res. 2015;7:527\u201335. https:\/\/doi.org\/10.2147\/ceor.S91587","journal-title":"Clinicoecon Outcomes Res"},{"key":"2663_CR8","unstructured":"European Committee on Antimicrobial Susceptibility Testing. Fluconazole: Rationale for the clinical breakpoints, version 3.0. https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Rationale_documents\/Fluconazole_RD_v3.0_final_18_02.pdf; 2020 [accessed 29 Jan 2025]."},{"key":"2663_CR9","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/0002-9343(94)90141-4","volume":"96","author":"MA Jacobson","year":"1994","unstructured":"Jacobson MA, Hanks DK, Ferrell LD. Fatal acute hepatic necrosis due to fluconazole. Am J Med. 1994;96:188\u201390. https:\/\/doi.org\/10.1016\/0002-9343(94)90141-4","journal-title":"Am J Med"},{"key":"2663_CR10","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1097\/00007691-200010000-00022","volume":"22","author":"K Matsumoto","year":"2000","unstructured":"Matsumoto K, Ueno K, Yoshimura H, Morii M, Takada M, Sawai T, et al. Fluconazole-Induced convulsions at serum trough concentrations of approximately 80 \u00b5g\/mL. Ther Drug Monit. 2000;22:635\u20136. https:\/\/doi.org\/10.1097\/00007691-200010000-00022","journal-title":"Ther Drug Monit"},{"key":"2663_CR11","unstructured":"Lewis R, Br\u00fcggemann R, Padoin C, Maertens J, Marchetti O, Groll A et al. Triazole antifungal therapeutic drug monitoring. Sixth European Conference on Infections in Leukaemia Meeting, Sophia Antipolis, France. https:\/\/www.ecil-leukaemia.com\/images\/resources\/2015\/5_ECIL6-Triazole-TDM-07-12-2015-Lewis-R-et-al.pdf; 2015 [accessed 29 Jan 2025]."},{"key":"2663_CR12","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","volume":"46","author":"MH Abdul-Aziz","year":"2020","unstructured":"Abdul-Aziz MH, Alffenaar J-WC, Bassetti M, Bracht H, Dimopoulos G, Marriott D, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position Paper#. Intensive Care Med. 2020;46:1127\u201353. https:\/\/doi.org\/10.1007\/s00134-020-06050-1","journal-title":"Intensive Care Med"},{"key":"2663_CR13","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1007\/s10096-021-04201-w","volume":"40","author":"I Sandaradura","year":"2021","unstructured":"Sandaradura I, Marriott DJE, Day RO, Norris RLG, Pang E, Stocker SL, et al. Current fluconazole treatment regimens result in under-dosing of critically ill adults during early therapy. Eur J Clin Microbiol Infect Dis. 2021;40:1521\u20138. https:\/\/doi.org\/10.1007\/s10096-021-04201-w","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2663_CR14","doi-asserted-by":"publisher","unstructured":"Boonstra JM, M\u00e4rtson AG, Sandaradura I, Kosterink JGW, van der Werf TS, Marriott DJE, et al. Optimization of fluconazole dosing for the prevention and treatment of invasive candidiasis based on the pharmacokinetics of fluconazole in critically ill patients. Antimicrob Agents Chemother. 2021;65. https:\/\/doi.org\/10.1128\/aac.01554-20","DOI":"10.1128\/aac.01554-20"},{"key":"2663_CR15","doi-asserted-by":"publisher","unstructured":"Muilwijk EW, de Lange DW, Schouten JA, Wasmann RE, Ter Heine R, Burger DM, et al. Suboptimal dosing of fluconazole in critically ill patients: time to rethink dosing. Antimicrob Agents Chemother. 2020;64. https:\/\/doi.org\/10.1128\/aac.00984-20","DOI":"10.1128\/aac.00984-20"},{"key":"2663_CR16","doi-asserted-by":"publisher","first-page":"6550","DOI":"10.1128\/aac.01088-16","volume":"60","author":"AS Alobaid","year":"2016","unstructured":"Alobaid AS, Wallis SC, Jarrett P, Starr T, Stuart J, Lassig-Smith M, et al. Effect of obesity on the population pharmacokinetics of fluconazole in critically ill patients. Antimicrob Agents Chemother. 2016;60:6550\u20137. https:\/\/doi.org\/10.1128\/aac.01088-16","journal-title":"Antimicrob Agents Chemother"},{"key":"2663_CR17","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1038\/psp.2013.14","volume":"2","author":"DR Mould","year":"2013","unstructured":"Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to Pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol. 2013;2:e38. https:\/\/doi.org\/10.1038\/psp.2013.14","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2663_CR18","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1023\/a:1011970125687","volume":"15","author":"EN Jonsson","year":"1998","unstructured":"Jonsson EN, Karlsson MO. Automated covariate model Building within NONMEM. Pharm Res. 1998;15:1463\u20138. https:\/\/doi.org\/10.1023\/a:1011970125687","journal-title":"Pharm Res"},{"key":"2663_CR19","doi-asserted-by":"publisher","first-page":"F632","DOI":"10.1152\/ajprenal.1984.247.4.F632","volume":"247","author":"P Boer","year":"1984","unstructured":"Boer P. Estimated lean body mass as an index for normalization of body fluid volumes in humans. Am J Physiol. 1984;247:F632\u20136. https:\/\/doi.org\/10.1152\/ajprenal.1984.247.4.F632","journal-title":"Am J Physiol"},{"key":"2663_CR20","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1002\/cpt.2489","volume":"112","author":"A Sharma","year":"2022","unstructured":"Sharma A, Sahasrabudhe V, Musib L, Zhang S, Younis I, Kanodia J. Time to rethink the current paradigm for assessing kidney function in drug development and beyond. Clin Pharmacol Ther. 2022;112:946\u201358. https:\/\/doi.org\/10.1002\/cpt.2489","journal-title":"Clin Pharmacol Ther"},{"key":"2663_CR21","doi-asserted-by":"publisher","unstructured":"Vuong M-L, Verbeke G, Dreesen E. A Multiple Imputation Workflow for Handling Missing Covariate Data in Pharmacometrics Modeling. CPT: Pharmacometrics & Systems Pharmacology. 2025;14:991\u20131005. https:\/\/doi.org\/10.1002\/psp4.70039","DOI":"10.1002\/psp4.70039"},{"key":"2663_CR22","doi-asserted-by":"crossref","unstructured":"van Buuren S. Flexible Imputation of Missing Data, Second Edition. New York: CRC Press; 2018.","DOI":"10.1201\/9780429492259"},{"key":"2663_CR23","doi-asserted-by":"crossref","unstructured":"Hosmer DW, Lemeshow S, May S. Applied Survival Analysis: Regression Modeling of Time-to-Event Data, Second Edition. New Jersey: John Wiley & Sons, Inc.; 2008.","DOI":"10.1002\/9780470258019"},{"key":"2663_CR24","unstructured":"Committee for Medicinal Products for Human Use (CHMP) EMA. Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antimicrobial medicinal products. United Kingdom: European Medicines Agency. 2016. Report No.: EMA\/CHMP\/594085\/2015. https:\/\/www.tga.gov.au\/sites\/default\/files\/2024-08\/guideline_on_the_use_of_pharmacokinetics_and_pharmacodynamics_in_the_development_of_antimicrobial_medicinal_products_.pdf"},{"key":"2663_CR25","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/B978-0-12-817815-7.00005-1","volume-title":"Mathematical statistics with applications in R (Third Edition)","author":"KM Ramachandran","year":"2021","unstructured":"Ramachandran KM, Tsokos CP. Chapter 5 - Statistical Estimation. In: Ramachandran KM, Tsokos CP, editors. Mathematical statistics with applications in R (Third Edition). London: Academic; 2021. pp. 179\u2013251."},{"key":"2663_CR26","volume-title":"R for data science: Import, Tidy, Transform, Visualize, and model data","author":"H Wickham","year":"2023","unstructured":"Wickham H, Cetinkaya-Rundel M, Grolemund G. R for data science: Import, Tidy, Transform, Visualize, and model data. 2nd ed. California: O\u2019Reilly Media; 2023.","edition":"2"},{"key":"2663_CR27","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1038\/psp.2013.24","volume":"2","author":"RJ Keizer","year":"2013","unstructured":"Keizer RJ, Karlsson MO, Hooker A. Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and xpose. CPT Pharmacometrics Syst Pharmacol. 2013;2:e50. https:\/\/doi.org\/10.1038\/psp.2013.24","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2663_CR28","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1093\/ndt\/gfi284","volume":"21","author":"R Bergner","year":"2006","unstructured":"Bergner R, Hoffmann M, Riedel KD, Mikus G, Henrich DM, Haefeli WE, et al. Fluconazole dosing in continuous veno-venous haemofiltration (CVVHF): need for a high daily dose of 800\u00a0mg. Nephrol Dial Transpl. 2006;21:1019\u201323. https:\/\/doi.org\/10.1093\/ndt\/gfi284","journal-title":"Nephrol Dial Transpl"},{"key":"2663_CR29","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s001340000771","volume":"27","author":"SL Buijk","year":"2001","unstructured":"Buijk SL, Gyssens IC, Mouton JW, Verbrugh HA, Touw DJ, Bruining HA. Pharmacokinetics of sequential intravenous and enteral fluconazole in critically ill surgical patients with invasive mycoses and compromised gastro-intestinal function. Intensive Care Med. 2001;27:115\u201321. https:\/\/doi.org\/10.1007\/s001340000771","journal-title":"Intensive Care Med"},{"key":"2663_CR30","doi-asserted-by":"publisher","unstructured":"Sinnollareddy MG, Roberts JA, Lipman J, Akova M, Bassetti M, De Waele JJ, et al. Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and Caspofungin in intensive care unit patients: data from multinational defining antibiotic levels in intensive care unit (DALI) patients study. Crit Care. 2015;19. https:\/\/doi.org\/10.1186\/s13054-015-0758-3","DOI":"10.1186\/s13054-015-0758-3"},{"key":"2663_CR31","doi-asserted-by":"publisher","unstructured":"Van Daele R, Wauters J, Lagrou K, Denooz R, Hayette MP, Gijsen M, et al. Pharmacokinetic variability and target attainment of fluconazole in critically ill patients. Microorganisms. 2021;9. https:\/\/doi.org\/10.3390\/microorganisms9102068","DOI":"10.3390\/microorganisms9102068"},{"key":"2663_CR32","doi-asserted-by":"publisher","first-page":"5868","DOI":"10.1128\/aac.00424-11","volume":"55","author":"K Patel","year":"2011","unstructured":"Patel K, Roberts JA, Lipman J, Tett SE, Deldot ME, Kirkpatrick CM. Population pharmacokinetics of fluconazole in critically ill patients receiving continuous venovenous hemodiafiltration: using Monte Carlo simulations to predict doses for specified pharmacodynamic targets. Antimicrob Agents Chemother. 2011;55:5868\u201373. https:\/\/doi.org\/10.1128\/aac.00424-11","journal-title":"Antimicrob Agents Chemother"},{"key":"2663_CR33","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/j.1365-2710.2011.01297.x","volume":"37","author":"T Aoyama","year":"2012","unstructured":"Aoyama T, Hirata K, Hirata R, Yamazaki H, Yamamoto Y, Hayashi H, et al. Population pharmacokinetics of fluconazole after administration of fosfluconazole and fluconazole in critically ill patients. J Clin Pharm Ther. 2012;37:356\u201363. https:\/\/doi.org\/10.1111\/j.1365-2710.2011.01297.x","journal-title":"J Clin Pharm Ther"},{"key":"2663_CR34","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1093\/jac\/dkac160","volume":"77","author":"L Chen","year":"2022","unstructured":"Chen L, van Rhee KP, Wasmann RE, Krekels EHJ, Wiezer MJ, van Dongen EPA, et al. Total bodyweight and sex both drive Pharmacokinetic variability of fluconazole in obese adults. J Antimicrob Chemother. 2022;77:2217\u201326. https:\/\/doi.org\/10.1093\/jac\/dkac160","journal-title":"J Antimicrob Chemother"},{"key":"2663_CR35","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1186\/s13054-022-04226-3","volume":"26","author":"C-Y Huang","year":"2022","unstructured":"Huang C-Y, G\u00fciza F, De Vlieger G, Meyfroidt G. Daily fluctuations in kidney function in critically ill adults. Crit Care. 2022;26:347. https:\/\/doi.org\/10.1186\/s13054-022-04226-3","journal-title":"Crit Care"},{"key":"2663_CR36","doi-asserted-by":"publisher","unstructured":"Sandaradura I, Wojciechowski J, Marriott DJE, Day RO, Stocker S, Reuter SE. Model-Optimized fluconazole dose selection for critically ill patients improves early pharmacodynamic target attainment without the need for therapeutic drug monitoring. Antimicrob Agents Chemother. 2021;65. https:\/\/doi.org\/10.1128\/aac.02019-20","DOI":"10.1128\/aac.02019-20"},{"key":"2663_CR37","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/qjmed\/hcs060","volume":"105","author":"S Darnis","year":"2012","unstructured":"Darnis S, Fareau N, Corallo CE, Poole S, Dooley MJ, Cheng AC. Estimation of body weight in hospitalized patients. QJM: Int J Med. 2012;105:769\u201374. https:\/\/doi.org\/10.1093\/qjmed\/hcs060","journal-title":"QJM: Int J Med"},{"key":"2663_CR38","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1002\/psp4.13002","volume":"12","author":"RC van Wijk","year":"2023","unstructured":"van Wijk RC, Imperial MZ, Savic RM, Solans BP. Pharmacokinetic analysis across studies to drive knowledge-integration: A tutorial on individual patient data meta-analysis (IPDMA). CPT Pharmacometrics Syst Pharmacol. 2023;12:1187\u2013200. https:\/\/doi.org\/10.1002\/psp4.13002","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2663_CR39","doi-asserted-by":"publisher","first-page":"786","DOI":"10.3389\/fphar.2020.00786","volume":"11","author":"L Li","year":"2020","unstructured":"Li L, Li X, Xia Y, Chu Y, Zhong H, Li J, et al. Recommendation of antimicrobial dosing optimization during continuous renal replacement therapy. Front Pharmacol. 2020;11:786. https:\/\/doi.org\/10.3389\/fphar.2020.00786","journal-title":"Front Pharmacol"},{"key":"2663_CR40","unstructured":"Zwep LB, Rongen Av, Allegaert K, Knibbe CAJ, Wijk RC. Statistical interaction modeling in non-linear mixed effect models: a case study in neonatal pharmacology. PAGE 32, 2024. Abstr 11035. [www.page-meeting.org\/?abstract=11035]"},{"key":"2663_CR41","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1186\/s13054-020-03057-4","volume":"24","author":"M Gijsen","year":"2020","unstructured":"Gijsen M, Wilmer A, Meyfroidt G, Wauters J, Spriet I. Can augmented renal clearance be detected using estimators of glomerular filtration rate? Crit Care. 2020;24:359. https:\/\/doi.org\/10.1186\/s13054-020-03057-4","journal-title":"Crit Care"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-025-02663-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-025-02663-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-025-02663-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T08:39:53Z","timestamp":1770021593000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-025-02663-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2663"],"URL":"https:\/\/doi.org\/10.1007\/s15010-025-02663-0","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"3 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ruth Van Daele contributed to this work while employed at KU Leuven and UZ Leuven. She is currently employed at Gilead Sciences. Omar Elkayal contributed to this work wile employed at KU Leuven. He is currently employed at Novo Nordisk.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the Ethics Committee Research UZ \/ KU Leuven (S62242).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent for the secondary use of prospectively collected data was obtained from participants of the original studies in compliance with the approval of the (local) Ethics Committees.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}